Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency

The antidiabetic drug metformin efficiently circumvents the dilemma that in reducing the tumourigenicity of stem cells, their essence, specifically their pluripotency, must also be sacrificed. Metformin prevents the occurrence or drastically reduces the size and weight of teratoma-like masses after...

Full description

Bibliographic Details
Main Authors:	Vazquez-Martin, Alejandro, Cufi, Sílvia, Lopez-Bonet, Eugeni, Corominas-Faja, Bruna, Oliveras-Ferraros, Cristina, Martin-Castillo, Begoña, Menendez, Javier A.
Format:	Online
Language:	English
Published:	Nature Publishing Group 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520055/

id	pubmed-3520055
recordtype	oai_dc
spelling	pubmed-35200552012-12-12 Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency Vazquez-Martin, Alejandro Cufi, Sílvia Lopez-Bonet, Eugeni Corominas-Faja, Bruna Oliveras-Ferraros, Cristina Martin-Castillo, Begoña Menendez, Javier A. Article The antidiabetic drug metformin efficiently circumvents the dilemma that in reducing the tumourigenicity of stem cells, their essence, specifically their pluripotency, must also be sacrificed. Metformin prevents the occurrence or drastically reduces the size and weight of teratoma-like masses after the transplantation of induced pluripotent stem (iPS) cells into immunodeficient mice. Yet, iPS cells implanted into metformin-treated mice retain full pluripotency, as they produce the same number of distinct tissue types derived from the three embryonic germ layers that is observed in untreated mice. Mechanistically, metformin appears to suppress the Oct4-driven compartment of malignant stem cells responsible for teratocarcinoma growth while safeguarding an intact, Oct4-independent competency to generate terminally differentiated tissues. Metformin's ability to efficiently and specifically control the tumourigenic fate of teratoma-initiating iPS cells without interfering with their pluripotency not only has implications for the clinical use of iPS cells but also in stem cell biology, cancer and ageing. Nature Publishing Group 2012-12-12 /pmc/articles/PMC3520055/ /pubmed/23236586 http://dx.doi.org/10.1038/srep00964 Text en Copyright © 2012, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Vazquez-Martin, Alejandro Cufi, Sílvia Lopez-Bonet, Eugeni Corominas-Faja, Bruna Oliveras-Ferraros, Cristina Martin-Castillo, Begoña Menendez, Javier A.
spellingShingle	Vazquez-Martin, Alejandro Cufi, Sílvia Lopez-Bonet, Eugeni Corominas-Faja, Bruna Oliveras-Ferraros, Cristina Martin-Castillo, Begoña Menendez, Javier A. Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency
author_facet	Vazquez-Martin, Alejandro Cufi, Sílvia Lopez-Bonet, Eugeni Corominas-Faja, Bruna Oliveras-Ferraros, Cristina Martin-Castillo, Begoña Menendez, Javier A.
author_sort	Vazquez-Martin, Alejandro
title	Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency
title_short	Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency
title_full	Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency
title_fullStr	Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency
title_full_unstemmed	Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency
title_sort	metformin limits the tumourigenicity of ips cells without affecting their pluripotency
description	The antidiabetic drug metformin efficiently circumvents the dilemma that in reducing the tumourigenicity of stem cells, their essence, specifically their pluripotency, must also be sacrificed. Metformin prevents the occurrence or drastically reduces the size and weight of teratoma-like masses after the transplantation of induced pluripotent stem (iPS) cells into immunodeficient mice. Yet, iPS cells implanted into metformin-treated mice retain full pluripotency, as they produce the same number of distinct tissue types derived from the three embryonic germ layers that is observed in untreated mice. Mechanistically, metformin appears to suppress the Oct4-driven compartment of malignant stem cells responsible for teratocarcinoma growth while safeguarding an intact, Oct4-independent competency to generate terminally differentiated tissues. Metformin's ability to efficiently and specifically control the tumourigenic fate of teratoma-initiating iPS cells without interfering with their pluripotency not only has implications for the clinical use of iPS cells but also in stem cell biology, cancer and ageing.
publisher	Nature Publishing Group
publishDate	2012
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520055/
_version_	1611939780267868160

Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency

Similar Items